Infliximab improved the refractory cutaneous involvement in a patient with dermatomyositis
Sign Up to like & getrecommendations! Published in 2019 at "Dermatologic Therapy"
DOI: 10.1111/dth.12859
Abstract: Dear Editor, Dermatomyositis skin lesions are often refractory to various therapies. Anti-tumor necrosis factor alpha (TNF-α) treatments, including infliximab, are now widely used for the treatment of autoimmune diseases, such as rheumatoid arthritis. Here, we… read more here.
Keywords: infliximab; cutaneous involvement; refractory cutaneous; dermatomyositis ... See more keywords